Vytorin Price Will Be Key To Impact In Cholesterol Market, AstraZeneca Says

The uptake of Vytorin (ezetimibe/simvastatin) will depend on the pricing strategy adopted by Merck and Schering-Plough, AstraZeneca CEO Tom McKillop predicted during a July 22 earnings call